Star Therapeutics raised $200 million in a financing described as a reset after earlier spinout successes that included a major sale of Vega Therapeutics to Incyte. The company said it is returning to an earlier-stage development posture, with plans to study additional biologics for hematological and immune conditions. The funding positions Star to re-enter stealth and rebuild a pipeline after leveraging offshoots such as Electra Therapeutics, which previously priced an IPO for a rare inflammatory program. For investors, the round signals continued appetite for platform-like rare-disease discovery models—particularly those that can create value through spinouts while preserving an operating core that can later reconstitute a pipeline.